Different antivascular endothelial growth factor treatments and regimens and their outcomes in neovascular age-related macular degeneration: A literature review

British Journal of Ophthalmology

Volumn 97, Issue 12, 2013, Pages 1497-1507

  Lanzetta, Paolo ^a   Mitchell, Paul ^b   Wolf, Sebastian ^c   Veritti, Daniele ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ARTERY THROMBOSIS; CEREBROVASCULAR ACCIDENT; DEATH; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; EYE DISEASE; FLUORESCENCE ANGIOGRAPHY; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MORPHOLOGY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; VASCULAR DISEASE; VISUAL ACUITY;

DRUGS; MACULA; NEOVASCULARISATION; TREATMENT MEDICAL;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84888643975     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2013-303394     Document Type: Review

References (46)

1. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-72. (Pubitemid 38456293)
2. International Diabetes Federation. The global burden. IDF Diabetes Atlas. http://www.diabetesatlas.org/bok/export/html/36 (accessed 17 Feb 2012).
3. Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Res 2011;47:171-88.
4. Kawasaki R, Yasuda M, Song SJ, et al. The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology 2010;117:921-7.
5. Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol 2012;153:209-13.
6. Skaat A, Chetrit A, Belkin M, et al. Time trends in the incidence and causes of blindness in Israel. Am J Ophthalmol 2012;153:214-21.
7. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65.
8. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31. (Pubitemid 44511557)
9. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus vertepor fin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44. (Pubitemid 44511558)
10. Almony A, Mansouri A, Shah GK, et al. Efficacy of intravitreal bevacizumab after unresponsive treatment with intravitreal ranibizumab. Can J Ophthalmol 2011;46:182-5.
11. Subramanian ML, Ness S, Abedi G, et al. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. Am J Ophthalmol 2009;148:875-82.
12. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
13. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98.
14. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-411.
15. Brand CS. Management of retinal vascular diseases: a patient-centric approach. Eye (Lond) 2012;26 (Suppl 2):S1-S16.
16. Oishi A, Mandai M, Nishida A, et al. Remission and dropout rate of anti-VEGF therapy for age-related macular degeneration. Eur J Ophthalmol 2011;21:777-82.
17. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 2010;150:315-24.
18. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-48.
19. Schmidt-Erfurth U, Eldem B, Guymer R, et al . Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011;118:831-9.
20. Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011;118:663-71.
21. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58.
22. Oubraham H, Cohen SY, Samimi S, et al. Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina 2011;31:26-30.
23. Holz FG, Korobelnik JF, Lanzetta P, et al. The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci 2010;51:405-12.
24. Lucentis [summary of product characteristics]. Huningue, France: Novartis Pharma SAS, 2013.
25. LUCENTIS (ranibizumab injection). Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda-docs/label/2006/125156lbl.pdf (accessed 14 Aug 2012).
26. Rotsos T, Patel PJ, Chen FK, et al. Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration. Clin Ophthalmol 2010;4:1271-5.
27. Michalova K, Wickremasinghe SS, Tan TH, et al. Ranibizumab treatment for neovascular age-related macular degeneration: from randomized trials to clinical practice. Eye (Lond) 2009;23:1633-40.
28. Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2012;119:1175-83.
29. Boyer DS, Heier JS, Brown DM, et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009;116:1731-9.
30. Department of Health and Human Services. BLA Approval. http://www accessdata. fda.gov/drugsatfda-docs/appletter/2011/125387s000ltr.pdf. (accessed 13 Jul 2012).
31. Australian Therapeutic Goods Administration. Final Decisions & Reasons for Decisions by Delegates of the Secretary to the Department of Health and Ageing. Australian Therapeutic Goods Administration. http://www.tga.gov.au/ pdf/scheduling/scheduling-decisions-1202-final.pdf (accessed 25 Jul 2012).
32. EYLEA [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc., 2011.
33. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 2008;92:667-8. (Pubitemid 351684178)
34. Stewart MW, Rosenfeld PJ, Penha FM, et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endotherlial growth factor trap-eye). Retina 2012;32:434-57.
35. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012;15:171-85.
36. American Academy of Ophthalmology Retina Panel. Preferred Practice Pattern Guidelines. Age-Related Macular Degeneration. American Academy of Ophthalmology Retina Panel. http://www.aao.org/ppp (accessed 27 Nov 2011).
37. The Royal College of Ophthalmologists. Age-Related Macular Degeneration Guidelines for Management. Internet site for Royal College of Opthalmologists. http://www.rcophth.ac.uk/page.asp?section=451§ionTitle= (accessed 18 Jun 2012).
38. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010;94:2-13.
39. Mitchell P. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. Curr Med Res Opin 2011;27:1465-75.
40. Montgomery AA, Peters TJ, Little P. Design, analysis and presentation of factorial randomised controlled trials. BMC Med Res Methodol 2003;3:26.
41. Nguyen QD, Heier J, Brown D, et al. Randomized, double-masked, active-controlled phase 3 trial of the efficacy and safety of intravitreal VEGF Trap-Eye in wet AMD: one-year results of the VIEW-1 study. Presented at: Association for Research in Vision and Ophthalmology; May 1-5, 2011; Fort Lauderdale, FL. Abstract 3073.
42. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-48.
43. Korobelnik JF. The VIEW-2 study -1 year results from a randomized, double masked, active controlled phase 3 trial of the efficacy and safety of intravitreal VEGF Trap-Eye in wet AMD. Presented at: European Society of Retinal Specialists Congress; May 26-29, 2011; London, UK.
44. Gater A, Thomson TA, Strandberg-Larsen M. Haemophilia B: impact on patients and economic burden of disease. Thromb Haemost 2011;106:398-404.
45. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001;15:1181-3. (Pubitemid 32549871)
46. Gross R, Bilker WB, Friedman HM, et al. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS 2001;15:2109-17. (Pubitemid 33101818)